Enveric Biosciences, Inc. (ENVB)
$1.52
+0.05 (+3.40%)
Rating:
Recommendation:
-
Symbol | ENVB |
---|---|
Price | $1.52 |
Beta | 0.192 |
Volume Avg. | 0.02M |
Market Cap | 3.528M |
Shares () | - |
52 Week Range | 1.3-6.98 |
1y Target Est | - |
DCF Unlevered | ENVB DCF -> | |
---|---|---|
DCF Levered | ENVB LDCF -> | |
ROE | -344.02% | Strong Sell |
ROA | -420.82% | Strong Sell |
Operating Margin | - | |
Debt / Equity | - | |
P/E | -0.13 | Neutral |
P/B | 1.35 | Strong Buy |
Latest ENVB news
About
Download (Excel)Dr. Joseph Edward Tucker Ph.D.
Healthcare
Biotechnology
NASDAQ Capital Market
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.